(Q22250988)

English

Metformin and body weight

scientific article

In more languages

Statements

scholarly article

0 references

0 references

1 reference

Europe PubMed Central

Metformin and body weight (English)

0 references

1 reference

based on heuristic

inferred from title

author name string

A Golay

1

author given names

A

author last names

Golay

1 reference

Dimensions Publication ID

7 February 2023

language of work or name

0 references

publication date

24 July 2007

0 references

International Journal of Obesity

0 references

32

0 references

1

0 references

61-72

0 references

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038/SJ.IJO.0803695

20 April 2017

Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance

1 reference

https://api.crossref.org/works/10.1038/SJ.IJO.0803695

20 April 2017

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

1 reference

https://api.crossref.org/works/10.1038/SJ.IJO.0803695

20 April 2017

Efficacy of metformin in the treatment of NIDDM. Meta-analysis

1 reference

https://api.crossref.org/works/10.1038/SJ.IJO.0803695

20 April 2017

Metformin in polycystic ovary syndrome: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1038/SJ.IJO.0803695

20 April 2017

Mechanism by which metformin reduces glucose production in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038/SJ.IJO.0803695

20 April 2017

The metabolic syndrome--a new worldwide definition

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803695

20 April 2017

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803695

20 April 2017

Current management strategies for coexisting diabetes mellitus and obesity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803695

21 January 2018

Incretins and other peptides in the treatment of diabetes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803695

21 January 2018

Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803695

21 January 2018

Link between obesity and type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803695

21 January 2018

Obesity and cardiovascular risk factors in type 2 diabetes: results from the Swedish National Diabetes Register.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803695

21 January 2018

Prevalence of obesity in type 2 diabetes in secondary care: association with cardiovascular risk factors.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803695

21 January 2018

Impact of overweight on the risk of developing common chronic diseases during a 10-year period

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803695

21 January 2018

The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803695

21 January 2018

Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803695

21 January 2018

High-fibre, low-fat diet predicts long-term weight loss and decreased type 2 diabetes risk: the Finnish Diabetes Prevention Study.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803695

21 January 2018

XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803695

21 January 2018

Effect of orlistat-induced weight loss on blood pressure and heart rate in obese patients with hypertension

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803695

21 January 2018

Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803695

21 January 2018

Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803695

21 January 2018

Effect of metformin on food intake in obese subjects.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803695

21 January 2018

Metformin decreases food consumption and induces weight loss in subjects with obesity with type II non-insulin-dependent diabetes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803695

21 January 2018

Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed Type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803695

21 January 2018

Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803695

21 January 2018

Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803695

21 January 2018

Rosiglitazone but not metformin enhances insulin- and exercise-stimulated skeletal muscle glucose uptake in patients with newly diagnosed type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803695

21 January 2018

Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: the Essen-II Study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803695

21 January 2018

Six-month efficacy of benfluorex vs. placebo or metformin in diet-failed type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803695

21 January 2018

PRESERVE-beta: two-year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803695

21 January 2018

One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803695

21 January 2018

Prospective comparative study in NIDDM patients of metformin and glibenclamide with special reference to lipid profiles

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803695

21 January 2018

Rosiglitazone/metformin fixed-dose combination compared with uptitrated metformin alone in type 2 diabetes mellitus: a 24-week, multicenter, randomized, double-blind, parallel-group study.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803695

21 January 2018

Effects of rosiglitazone added to submaximal doses of metformin compared with dose escalation of metformin in type 2 diabetes: the EMPIRE Study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803695

21 January 2018

The effects of high- and medium-dose metformin therapy on cardiovascular risk factors in patients with type II diabetes.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803695

21 January 2018

Double-blind evaluation of efficacy and tolerability of metformin in NIDDM.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803695

21 January 2018

Glyburide/metformin tablets: a new therapeutic option for the management of Type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803695

21 January 2018

Differential effects of rosiglitazone and metformin on adipose tissue distribution and glucose uptake in type 2 diabetic subjects

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803695

21 January 2018

Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbA1c. IOEZ Study Group.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803695

21 January 2018

Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803695

21 January 2018

Long-term glycaemic improvement after addition of metformin to insulin in insulin-treated obese type 2 diabetes patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803695

21 January 2018

Continuing metformin when starting insulin in patients with Type 2 diabetes: a double-blind randomized placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803695

21 January 2018

Combined metformin and insulin therapy for patients with type 2 diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803695

21 January 2018

Combination of insulin and metformin in the treatment of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803695

21 January 2018

Biphasic insulin aspart 30 plus metformin: an effective combination in type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803695

21 January 2018

Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and troglitazone in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803695

21 January 2018

The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803695

21 January 2018

Intensive insulin therapy combined with metformin in obese type 2 diabetic patients.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803695

21 January 2018

Causes of weight gain during insulin therapy with and without metformin in patients with Type II diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803695

21 January 2018

Adding metformin versus insulin dose increase in insulin-treated but poorly controlled Type 2 diabetes mellitus: an open-label randomized trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803695

21 January 2018

Energy expenditure in non-insulin dependent diabetic subjects on metformin or sulphonylurea therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803695

21 January 2018

Modulation of hunger by plasma glucose and metformin.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803695

21 January 2018

Inhibition of leptin secretion by insulin and metformin in cultured rat adipose tissue

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803695

21 January 2018

The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution. BIGPRO Study Group.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803695

21 January 2018

Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803695

21 January 2018

Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803695

21 January 2018

Metformin reduces weight, centripetal obesity, insulin, leptin, and low-density lipoprotein cholesterol in nondiabetic, morbidly obese subjects with body mass index greater than 30.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803695

21 January 2018

Metformin as treatment for overweight and obese adults: a systematic review

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803695

21 January 2018

Long-term (2-4 year) weight reduction with metformin plus carbohydrate-modified diet in euglycemic, hyperinsulinemic, midlife women (Syndrome W).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803695

21 January 2018

Metformin and carbohydrate-modified diet: a novel obesity treatment protocol: preliminary findings from a case series of nondiabetic women with midlife weight gain and hyperinsulinemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803695

21 January 2018

Syndrome W: a new model of hyperinsulinemia, hypertension and midlife weight gain in healthy women with normal glucose tolerance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803695

21 January 2018

The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803695

21 January 2018

Metabolic effects of metformin in patients with impaired glucose tolerance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803695

21 January 2018

Therapeutic strategies for ovulation induction in infertile women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803695

21 January 2018

A randomized, 48-week, placebo-controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803695

21 January 2018

Metformin and weight loss in obese women with polycystic ovary syndrome: comparison of doses

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803695

21 January 2018

Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803695

21 January 2018

Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803695

21 January 2018

Effect of metformin in pediatric patients with type 2 diabetes: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803695

21 January 2018

Glimepiride versus metformin as monotherapy in pediatric patients with type 2 diabetes: a randomized, single-blind comparative study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803695

21 January 2018

The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803695

21 January 2018

Randomized, controlled trial of metformin for obesity and insulin resistance in children and adolescents: improvement in body composition and fasting insulin.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803695

21 January 2018

Improved endothelial function with metformin in type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803695

21 January 2018

Metformin administration improves endothelial function in women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803695

21 January 2018

Metformin: intrinsic vasculoprotective properties

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803695

21 January 2018

Drug-induced weight gain.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803695

21 January 2018

An approach to the management of unintentional weight loss in elderly people

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803695

21 January 2018

The effect of obesity on glycaemic response to metformin or sulphonylureas in Type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803695

21 January 2018

Initiating oral glucose-lowering therapy with metformin in type 2 diabetic patients: an evidence-based strategy to reduce the burden of late-developing diabetes complications

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803695

21 January 2018

The Diabetes Prevention Program: baseline characteristics of the randomized cohort. The Diabetes Prevention Program Research Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803695

7 January 2021

based on heuristic

inferred from DOI database lookup

[Nationwide multicenter study on the prevalence of overweight and obesity in type 2 diabetes mellitus in the Brazilian population]

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803695

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of abdominal adiposity and overall obesity in predicting risk of type 2 diabetes among men

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803695

7 January 2021

based on heuristic

inferred from DOI database lookup

Incidence of type 2 diabetes in individuals with central obesity in a rural Japanese population: The Tanno and Sobetsu study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803695

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803695

7 January 2021

based on heuristic

inferred from DOI database lookup

Reducing insulin resistance with metformin: the evidence today

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803695

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of metformin in patients with poorly controlled, insulin-treated type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803695

7 January 2021

based on heuristic

inferred from DOI database lookup

Metformin added to insulin therapy in poorly controlled type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803695

7 January 2021

based on heuristic

inferred from DOI database lookup

Anorectic effect of metformin in obese Zucker rats: lack of evidence for the involvement of neuropeptide Y

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803695

7 January 2021

based on heuristic

inferred from DOI database lookup

Metformin and brown adipose tissue thermogenetic activity in genetically obese Zucker rats

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803695

7 January 2021

based on heuristic

inferred from DOI database lookup

Decreased serum leptin concentrations during metformin therapy in obese women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803695

7 January 2021

based on heuristic

inferred from DOI database lookup

The insulin-sparing effect of metformin in insulin-treated diabetic patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803695

7 January 2021

based on heuristic

inferred from DOI database lookup

Worldwide experience of metformin as an effective glucose-lowering agent: a meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803695

7 January 2021

based on heuristic

inferred from DOI database lookup

Metformin monotherapy for type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803695

7 January 2021

based on heuristic

inferred from DOI database lookup

Potential contribution of metformin to the management of cardiovascular disease risk in patients with abdominal obesity, the metabolic syndrome and type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803695

7 January 2021

based on heuristic

inferred from DOI database lookup

Do effects on blood pressure contribute to improved clinical outcomes with metformin?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803695

7 January 2021

based on heuristic

inferred from DOI database lookup

Mitochondrial metabolism and type-2 diabetes: a specific target of metformin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803695

7 January 2021

based on heuristic

inferred from DOI database lookup

Beneficial effects of metformin on haemostasis and vascular function in man.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803695

7 January 2021

based on heuristic

inferred from DOI database lookup

Metformin inhibition of glycation processes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803695

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of tolbutamide and metformin in elderly diabetic patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803695

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q22250988&oldid=2175168732"